SNX631-6 / Senex Biotech - LARVOL DELTA

Targeting Mediator Kinase Cyclin-Dependent Kinases 8/19 Potentiates Chemotherapeutic Responses, Reverses Tumor Growth, and Prolongs Survival from Ovarian Clear Cell Carcinoma. (PubMed, Cancers (Basel)) - "Therapeutically achievable doses of CDK8/19 inhibitors may provide clinical benefit for OCCC patients by inhibiting tumor growth and reversing platinum resistance, potentially addressing a critical treatment challenge in this rare ovarian cancer subtype."

Journal • Clear Cell Carcinoma • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Ovarian Clear Cell Cancer • Solid Tumor

Senex Awarded STTR Grant from National Cancer Institute for CDK8/19 Inhibition as Treatment of Metastatic Ovarian Cancer (EIN News) - "Senex Biotechnology announced today the award of a $400,000 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute, part of the National Institutes of Health (NIH). The grant will fund the development of a novel formulation of SNX631-6, the Company’s CDK8/19 Mediator kinase inhibitor and clinical candidate as a treatment for metastatic ovarian cancer (OC)...This project will be supported by an NIH grant R41CA298223."

Financing • Ovarian Cancer